SCUELJapan healthcare data

Home › Japan pharmaceutical market › Dihydropyridine calcium channel blockers

Japan market size · Drug class

Dihydropyridine calcium channel blockers in Japan

Ca拮抗薬（ジヒドロピリジン系）

The prescription value of Dihydropyridine calcium channel blockers (11 molecules) in Japan was an estimated ¥69.2 billion in FY2024. Value changed -8.3% year on year and -9.0% a year on average over the last three years. The largest molecule is Amlodipine Besilate (65%). In addition, 9 combination products totalled ¥46.9 billion.

¥69.2bnValue FY2024 (single agents)
-8.3%Year on year
-9.0%3-year average growth

Trend and molecules

Hover or tap a year for the values.

Trend (single agents)

Prescription value (est.)YoY upYoY down

By molecule (FY2021 = 100)

Molecules in this class

Amlodipine Besilateアムロジピンベシル酸塩NifedipineニフェジピンCilnidipineシルニジピンBenidipine Hydrochlorideベニジピン塩酸塩AzelnidipineアゼルニジピンNicardipine Hydrochlorideニカルジピン塩酸塩Efonidipine Hydrochloride Ethanolateエホニジピン塩酸塩エタノール付加物Manidipine Hydrochlorideマニジピン塩酸塩Barnidipine Hydrochlorideバルニジピン塩酸塩NitrendipineニトレンジピンFelodipineフェロジピンAzilsartan / Amlodipine Besilateアジルサルタン・アムロジピンベシル酸塩Telmisartan / Amlodipine Besilateテルミサルタン・アムロジピンベシル酸塩Irbesartan / Amlodipine Besilateイルベサルタン・アムロジピンベシル酸塩カンデサルタンシレキセチル・アムロジピンベシル酸塩カンデサルタンシレキセチル・アムロジピンベシル酸塩オルメサルタンメドキソミル・アゼルニジピンオルメサルタンメドキソミル・アゼルニジピンAmlodipine Besilate / Atorvastatin Calcium Hydrateアムロジピンベシル酸塩・アトルバスタチンカルシウム水和物Valsartan / Amlodipine Besilateバルサルタン・アムロジピンベシル酸塩Valsartan / Cilnidipineバルサルタン・シルニジピンTelmisartan / Amlodipine Besilate / Hydrochlorothiazideテルミサルタン・アムロジピンベシル酸塩・ヒドロクロロチアジド
All markets

Need the numbers behind the lines?

Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.

Contact us

About the data

Values are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.